Clinical Trials Browser

Completed × OTHER × Afatinib × Clear all

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01783587 2025-05-01

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

Phase 2 Completed

Chordoma

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04839471 2024-07-08

BEAR

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

Phase 2 Completed

Neoplasm Metastasis

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01522768 2023-11-01

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2 Completed

42 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02506517 2023-08-01

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Phase 2 Completed

Other solid neoplasm

Solid Tumors

NCT02501603 2023-01-27

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04201756 2022-12-23

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02451553 2022-06-07

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT02423525 2022-03-10

Safety Study of Afatinib for Brain Cancer

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Meningeal Carcinomatosis

NCT01415674 2022-02-02

PREDICTOR

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02629523 2021-08-03

LiquidLung-A

Phase 2 Completed

Lung Neoplasms

NCT01427478 2021-06-01

BIBW2992ORL

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT04640870 2020-12-23

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Lung Neoplasms, Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01919879 2018-05-08

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01074177 2018-03-09

Understanding Mechanisms of Acquired Resistance to BIBW2992

Phase NA Completed

24 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02216617 2017-10-27

TAPIS

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01721525 2017-10-25

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Phase 1 Completed

Head and Neck Neoplasms, Neoplasms, Squamous Cell